A coronavirus vaccine (Ad5-nCoV) has received special military drug approval

  • Ad5-nCoV is currently limited to military use
  • cannot be expanded to a broader vaccination range without further government approval

News via the Global Times.


  • Chinese biopharmaceutical firm CanSino Biologics Inc developed the vaccine in conjunction with a military research team
  • jointly developed by CanSino and the Institute of Biotechnology under the Academy of Military Medical Sciences
  • Phase 1 and phase 2 clinical trials for Ad5-nCoV have been conducted
  • The overall clinical results indicate Ad5-nCoV has the potential to prevent diseases caused by SARS-CoV-2.

GT adds this:

  • CanSino announced its collaboration with the Canadian National Research Council on clinical trials for the recombinant vaccine in May


This sort of news asks as a positive for risk trades.